Karyopharm Therapeutics (NASDAQ:KPTI) Director Mansoor Raza Mirza sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $17.01, for a total transaction of $42,525.00. Following the completion of the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $42,525. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of KPTI stock opened at $12.48 on Friday. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $18.00. The stock has a market cap of $645.49, a P/E ratio of -4.44 and a beta of 3.61.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $2.26 million. The business’s revenue was up 3163.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.65) earnings per share. equities analysts predict that Karyopharm Therapeutics will post -2.83 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $115,000. Voya Investment Management LLC lifted its stake in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $146,000. Two Sigma Investments LP lifted its stake in shares of Karyopharm Therapeutics by 76.8% in the 4th quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after purchasing an additional 10,520 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after purchasing an additional 5,586 shares during the period. 62.45% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently issued reports on KPTI. BidaskClub raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. Robert W. Baird set a $22.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, January 25th. JPMorgan Chase restated an “overweight” rating and issued a $19.00 price objective (up from $18.00) on shares of Karyopharm Therapeutics in a report on Friday, March 16th. Finally, ValuEngine upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $20.10.
ILLEGAL ACTIVITY NOTICE: “Karyopharm Therapeutics (NASDAQ:KPTI) Director Sells $42,525.00 in Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/karyopharm-therapeutics-inc-kpti-director-mansoor-raza-mirza-sells-2500-shares-of-stock.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.